ADC Therapeutics SA
ADCT3.120USD
-0.160-4.88%
Cierre 07/28, 16:00（ET）Cotizaciones retrasadas 15 min
309.44MCap. mercado
PérdidaP/E TTM
Más Datos de ADC Therapeutics SA Compañía
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Información de la empresa
Símbolo de cotizaciónADCT
Nombre de la empresaADC Therapeutics SA
Fecha de salida a bolsaMay 15, 2020
Fundada en2011
Director ejecutivoMr. Ameet Mallik
Número de empleados263
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
DirecciónBiopole
CiudadEPALINGES
Bolsa de valoresNYSE Consolidated
PaísSwitzerland
Código postal1066
Teléfono41216530200
Sitio Webhttps://adctherapeutics.com/
Símbolo de cotizaciónADCT
Fecha de salida a bolsaMay 15, 2020
Fundada en2011
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Dr. Tyrell J. Rivers, Ph.D.
Dr. Tyrell J. Rivers, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 19 de jun
Actualizado: jue., 19 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
Accionistas
Accionistas
Proporción
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
26.07%
Hedge Fund
18.79%
Corporation
15.04%
Investment Advisor
7.91%
Research Firm
7.20%
Individual Investor
6.59%
Private Equity
6.02%
Bank and Trust
0.83%
Insurance Company
0.02%
Other
11.53%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
208
88.44M
89.17%
-13.33M
2025Q1
217
80.51M
81.56%
-23.93M
2024Q4
219
81.03M
83.80%
-19.29M
2024Q3
223
79.78M
82.57%
-21.86M
2024Q2
215
76.61M
81.35%
-7.96M
2024Q1
177
59.13M
71.30%
-27.56M
2023Q4
169
58.32M
71.49%
-25.86M
2023Q3
180
68.48M
85.02%
-18.63M
2023Q2
182
74.11M
92.00%
-12.88M
2023Q1
185
75.45M
93.66%
-4.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Redmile Group, LLC
15.67M
15.8%
--
--
Mar 31, 2025
Prosight Capital
9.54M
9.62%
+28.00K
+0.29%
Mar 31, 2025
HPWH TH AG
8.67M
8.74%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.83M
7.9%
+7.83M
--
Jun 16, 2025
OrbiMed Advisors, LLC
5.97M
6.02%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
4.54%
-88.38K
-1.93%
Mar 31, 2025
Oaktree Capital Management, L.P.
4.02M
4.05%
+4.02M
--
Apr 25, 2024
AstraZeneca (UK) Ltd.
4.01M
4.04%
--
--
Dec 31, 2023
Morgan Stanley & Co. LLC
2.96M
2.98%
-968.19K
-24.66%
Mar 31, 2025
Auven Therapeutics General LP
2.23M
2.25%
-4.10M
-64.75%
Apr 23, 2024
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Ver más
iShares Micro-Cap ETF
Proporción0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
